FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期： 2024年11月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 人工晶狀體植入系統獲得醫療器械註冊證 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本集團全資附屬公司高視泰靚 醫療科技有限公司（「高視泰靚」）之「人工晶狀體植入系統」已獲得由廣東省藥 品監督管理局批准的二類醫療器械註冊證。 高 視 泰 靚 本 次 獲 批 的 人 工 晶 狀 體 植 入 系 統（註 冊 證 編 號 ： 粵 械 注 准 20242161490）由高視泰靚自主設計完成，既可以用於白內障手術中的人工晶狀 體植入手術，也可用於矯正近視的有晶體眼人工晶狀體植入手術。該產品一方 面可滿足本 ...

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of RMB 642.0 million, a decrease of 8.4% compared to RMB 700.7 million for the same period in 2023[23]. - The net profit for the same period was RMB 26.9 million, down 75.6% from RMB 110.4 million in the prior year[23]. - Basic earnings per share for the six months ended June 30, 2024, were RMB 0.19, compared to RMB 0.75 for the same period in 2023[23]. - Total revenue for the six months ended June 30, 2024, was RMB 529.1 million, a decrease of 10.8% from RMB 593.2 million for the same period in 2023[39]. - Gross profit decreased by 16.1% to RMB 298.4 million for the six months ended June 30, 2024, compared to RMB 355.6 million for the same period in 2023, with a gross margin decline from 50.8% to 46.5%[40]. - The technical services segment generated revenue of RMB 110.0 million, representing a year-on-year increase of 6.5%[29]. - Profit before tax decreased to RMB 58,395,000, a decline of 58.9% from RMB 142,229,000 in the previous year[100]. - Total comprehensive income for the period was RMB 7,110,000, down from RMB 147,170,000 in the same period last year[103]. Research and Development - Research and development expenses increased by 34.5% to RMB 35.1 million, representing 5.5% of revenue, up from 3.7% in the previous year[23]. - The company has expanded its R&D capabilities with platforms in four cities in China and two in Europe, covering a global sales network across 51 countries[25]. - The company has established a "global 4+2" R&D layout with a total of 261 R&D personnel, representing approximately 29.9% of total employees[30]. - Research and development expenses rose by 34.5% to RMB 35.1 million, reflecting ongoing investments in product development and team expansion[47]. - Research and development expenses increased to RMB 35,140,000, up 34.6% from RMB 26,105,000 in the previous year[123]. Product and Market Development - The company has a product portfolio of 150 items, including 65 proprietary products, and has established exclusive distribution agreements with 16 overseas brand partners[25][28]. - Revenue contribution from proprietary products was RMB 178.0 million, accounting for 33.6% of total sales, an increase from 32.7% in the previous year[27]. - The company is focusing on the development of surgical treatment products, particularly surgical equipment and consumables[35]. - The company has expanded its distribution network, partnering with 18 overseas brands, including exclusive agreements with 16 partners[33]. - The company aims to enhance its operational efficiency and strengthen brand and talent development as part of its long-term strategy[35]. Financial Position and Cash Flow - Cash and cash equivalents decreased by 11.6% from RMB 618.7 million as of December 31, 2023, to RMB 546.8 million as of June 30, 2024, mainly due to repayment of domestic loans[61]. - The debt-to-asset ratio increased from 39.1% as of December 31, 2023, to 40.2% as of June 30, 2024[65]. - Total liabilities decreased to RMB 1,251,830,000 from RMB 1,146,731,000 at the end of 2023, indicating a shift in financial structure[105]. - Operating cash flow for the six months ended June 30, 2024, was RMB (10,829) thousand, a significant decrease from RMB 111,187 thousand in the same period of 2023[109]. - The company reported a net cash outflow from financing activities of RMB (59,304) thousand in 2024, compared to RMB (70,433) thousand in 2023, indicating a decrease in outflow of about 16%[110]. Shareholder Information - The largest shareholder, GT HoldCo, holds 42.75% of the issued share capital, amounting to 63,263,528 shares[90]. - As of June 30, 2024, the company had a total of 147,970,369 issued ordinary shares[2]. - The board of directors did not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous year[77]. - The company has adopted a share incentive plan to recognize and reward contributions from eligible participants, with no rewards granted under this plan as of the interim report date[72]. Foreign Exchange and Risk Management - The company reported a foreign exchange loss of RMB 198 million due to fluctuations in the Euro exchange rate during the reporting period[67]. - The company has no foreign currency hedging policy in place and continues to monitor foreign exchange risks[67]. - The company has implemented a credit verification process for all traders engaging in credit transactions[68]. Employee and Management Information - The total employee cost for the reporting period was RMB 184 million, an increase from RMB 169.6 million for the same period last year[71]. - The company had a total of 872 employees as of June 30, 2024, compared to 869 employees as of December 31, 2023[71]. - Total remuneration for key management personnel reached RMB 4,263,000 for the six months ended June 30, 2024, up from RMB 3,632,000 in 2023, reflecting a growth of 17.4%[162]. Acquisitions and Investments - The company completed the acquisition of Teleon Holding B.V. for €24.25 million, enhancing its product portfolio[174]. - The group’s investment in private equity funds amounted to RMB 178,696,000, with an expected return rate between 2.5% and 4.5% annually[143].

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of RMB 642.0 million, a decrease of 8.4% compared to RMB 700.7 million in the same period of 2023[2]. - The net profit for the same period was RMB 26.9 million, down 75.6% from RMB 110.4 million in 2023[2]. - Basic earnings per share were RMB 0.19, compared to RMB 0.75 in the same period of 2023[2]. - Gross profit fell from RMB 355.6 million for the six months ended June 30, 2023, to RMB 298.4 million for the same period in 2024, a decrease of 16.1%[17]. - The gross margin decreased from 50.8% to 46.5%, mainly due to increased raw material and labor costs, changes in product sales mix, and a significant price drop for artificial lenses starting May 2024[18]. - Total comprehensive income for the period was RMB 7,110 thousand, significantly lower than RMB 147,170 thousand in 2023[60]. - The company's total equity was RMB 1,555,941 thousand, down from RMB 1,696,986 thousand at the end of 2023[63]. Revenue Breakdown - Revenue contribution from proprietary products was RMB 178.0 million, accounting for 33.6% of total sales, an increase from 32.7% in the previous year[6]. - Revenue from distribution products was RMB 351.0 million, a decrease of 12.1% due to ongoing impacts from domestic medical service policies and macroeconomic conditions[7]. - Revenue from self-owned products was RMB 178,005,000, down from RMB 193,868,000, representing a decline of 8.9%[67]. - Revenue from distribution products was RMB 351,048,000, a decrease of 12.1% from RMB 399,365,000[67]. - Revenue from ophthalmic medical devices was RMB 273,009,000, down from RMB 337,863,000, a decrease of 19.3%[70]. - Revenue from technical services increased to RMB 110,047,000, up from RMB 103,325,000, marking a growth of 6.6%[70]. Research and Development - Research and development expenses increased by 34.5% to RMB 35.1 million, representing 5.5% of revenue, up from 3.7% in 2023[2]. - The company's R&D expenditure reached RMB 35.1 million, a year-on-year increase of 34.5%, accounting for 19.7% of self-owned product revenue[9]. - The company has accelerated the development of domestic artificial lenses, obtaining medical device registration certificates ahead of schedule[4]. - The company has established a global R&D layout of "4+2" with 261 R&D personnel, representing approximately 29.9% of total employees[9]. - The company is investing €5 million in R&D for the development of advanced ophthalmic devices[99]. Expenses and Costs - Sales and distribution expenses slightly decreased by 4.5% to RMB 115.5 million, while the percentage of these expenses to revenue increased from 17.3% to 18.0%[21]. - Administrative expenses increased by 17.8% to RMB 73.6 million, mainly due to staff expansion in administrative departments[22]. - Financing costs decreased by 13.1% to RMB 20.6 million, attributed to the repayment of domestic loans and lower interest rates on new loans[23]. - Other expenses rose significantly from RMB 1.9 million to RMB 12.0 million, mainly due to increased inventory impairment provisions and foreign exchange losses[25]. Inventory and Assets - Inventory increased by 11.6% to RMB 366.7 million, leading to an increase in inventory turnover days from 159 to 187 days[29]. - Non-current assets totaled RMB 1,421,150 thousand as of June 30, 2024, compared to RMB 1,452,881 thousand at the end of 2023[61]. - Current assets amounted to RMB 1,386,621 thousand, slightly down from RMB 1,390,836 thousand at the end of 2023[61]. - Trade receivables, net of impairment, amounted to RMB 143,783,000 as of June 30, 2024, compared to RMB 146,543,000 as of December 31, 2023[87]. Liabilities and Financing - The group's interest-bearing bank and other borrowings amounted to RMB 568.2 million as of June 30, 2024, including short-term borrowings of RMB 216.2 million and long-term borrowings of RMB 352.0 million[38]. - The debt-to-asset ratio increased from 39.1% as of December 31, 2023, to 40.2% as of June 30, 2024[40]. - The company plans to utilize a financing agreement of EUR 52.5 million to refinance existing loans, with a maturity date set for December 22, 2027[92]. Market and Strategic Initiatives - The company plans to enhance its product offerings in surgical treatment, focusing on surgical equipment and consumables[13]. - The company aims to strengthen its market presence in Asia and Europe while balancing domestic and international business growth[13]. - Market expansion efforts are focused on the Greater China region, with a target of increasing market share by 10%[97]. - The company has completed the acquisition of Teleon Holding B.V. for €24.25 million, enhancing its product portfolio[98]. - The company plans to enhance its distribution network in Europe, aiming for a 15% increase in sales through new partnerships[99]. Shareholder Returns and Dividends - The board does not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous period[49]. - The company announced a proposed final dividend of HKD 1.10 per share for the year ended December 31, 2023[82]. Audit and Compliance - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with financial reporting and risk management[54]. - The interim condensed consolidated financial statements for the six months ended June 30, 2024, were reviewed by the external auditor, Ernst & Young[56].

Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 1,406.2 million, an increase of 12.2% compared to RMB 1,253.8 million for the year ended December 31, 2022[8]. - The net profit for the year ended December 31, 2023, was RMB 172.9 million, a significant improvement from a net loss of RMB 352.7 million in 2022, and an increase of 9.9% compared to the adjusted net profit of RMB 157.3 million for 2022[8]. - Basic earnings per share for the year ended December 31, 2023, were RMB 1.17, compared to a basic loss per share of RMB 3.61 for the year ended December 31, 2022[8]. - The gross profit for the year was RMB 691.6 million, an increase of 10.6% compared to the previous year[14]. - The company's revenue increased by 12.2% from RMB 1,253.8 million in 2022 to RMB 1,406.2 million in 2023, driven by higher sales of ophthalmic medical consumables and equipment[30]. - The gross profit increased by 10.6% from RMB 625.3 million in 2022 to RMB 691.6 million in 2023, with a slight decrease in gross margin from 49.9% to 49.2% due to rising material costs[33]. Dividend and Shareholder Information - The board proposed a final dividend of HKD 1.1 per share for the year ended December 31, 2023, compared to no dividend in 2022[8]. - The annual general meeting for shareholder approval of the proposed dividend is scheduled for May 30, 2024[8]. - The expected distribution date for the approved dividend is July 26, 2024[8]. - The company’s distributable reserves as of December 31, 2023, were approximately RMB 855.4 million, an increase from RMB 822.2 million as of December 31, 2022[100]. Research and Development - The company has been engaged in research and development of a wide range of ophthalmic medical equipment and consumables for over 20 years[3]. - The company has established a global "4+2" R&D layout, with domestic bases in four Chinese cities and two overseas in the Netherlands and Germany[14]. - The company plans to increase investment in R&D and production, focusing on expanding its product range and enhancing its presence in high-end medical devices[11]. - The company's R&D expenditure was RMB 52.9 million, accounting for 13.9% of proprietary product revenue, a 28.7% increase from RMB 41.1 million in 2022[22]. - The company has established a "Global 4+2" R&D layout with 240 R&D personnel, representing approximately 28% of total employees, and significant investments in various ophthalmic products[22]. Product Development and Market Strategy - The company launched several new products, including a domestically produced rigid gas permeable contact lens and an automated fundus camera, which have shown strong market demand[14]. - The company aims to leverage its extensive experience and product range to capture growth opportunities in the ophthalmic sector[3]. - The company plans to expand its market presence and enhance its product offerings through new technology development and strategic initiatives[3]. - The company is focusing on expanding its presence in Asia and Europe while maintaining its leadership position in the Chinese market[29]. Sales and Revenue Breakdown - Sales of ophthalmic medical equipment reached RMB 680.3 million, while sales of consumables amounted to RMB 510.5 million, both showing growth compared to the previous year[15]. - Revenue from the company's distribution products amounted to RMB 808.9 million, reflecting an 8.6% increase from RMB 744.8 million in 2022, driven by product updates and enhanced marketing efforts[19]. - The revenue contribution from the company's proprietary products reached RMB 381.9 million, accounting for 32.1% of total sales, an increase from 29.3% in 2022, with a year-on-year growth of 23.9%[18]. - The technical services segment generated revenue of RMB 209.2 million, representing a 10.0% year-on-year increase, with over 26,000 service instances provided during the reporting period[21]. Operational and Financial Management - The company has a strong focus on compliance and internal audit, led by Mr. Zhao as the Chief Compliance Officer[68]. - The company’s financial management is overseen by Ms. Li, who has over 21 years of experience in accounting and finance[70]. - The company has maintained a robust cash flow and financial resources to support its operational and expansion needs[56]. - The company recorded income tax expenses of RMB 74.8 million for the year ended December 31, 2023, compared to RMB 77.6 million in 2022[42]. Corporate Governance and Leadership - The company has adopted a corporate governance code to maintain high standards of corporate governance and protect shareholder interests[132]. - The board consists of five executive directors, one non-executive director, and three independent non-executive directors as of December 31, 2023[138]. - The independent non-executive directors play a crucial role in providing impartial views on the company's strategy and performance[141]. - The company has established three board committees: the Audit Committee, the Remuneration Committee, and the Nomination Committee to oversee specific aspects of its affairs[137]. Social Responsibility and ESG Commitment - The company is committed to fulfilling social responsibilities and promoting sustainable growth, as detailed in the Environmental, Social, and Governance report[90]. - The company has identified 21 ESG issues categorized into environmental, social, and governance aspects, with high importance placed on product quality and safety, compliance employment, employee training and development, supply chain management, responsible marketing, information security and privacy protection, and anti-corruption[197]. - The company emphasizes the importance of anti-corruption and risk management in its operations, particularly in compliance with regulations and environmental management[196]. Employee and Talent Management - The total employee cost amounted to RMB 352.5 million, an increase from RMB 288.4 million as of December 31, 2022, reflecting a growth of approximately 22.3%[108]. - The number of employees increased to 869 as of December 31, 2023, up from 790 as of December 31, 2022, indicating a growth of over 10%[108]. - The company emphasizes employee training and development, continuously enhancing its training management system to support long-term high-quality growth[108]. Risk Management and Compliance - The company has established a risk management and internal control system to ensure high levels of corporate governance and to identify and mitigate potential risks[175]. - The board reviewed the effectiveness of the risk management and internal control system for the year ending December 31, 2023, ensuring compliance with established procedures and standards[176]. - The internal audit function plays a key role in monitoring the company's internal governance and reports significant issues to the audit committee[176].

Financial Performance - For the year ended December 31, 2023, the company's revenue was RMB 1,406.2 million, an increase of 12.2% compared to RMB 1,253.8 million for the year ended December 31, 2022[2]. - The net profit for the year ended December 31, 2023, was RMB 172.9 million, a significant recovery from a net loss of RMB 352.7 million in the previous year[2]. - The basic earnings per share for the year ended December 31, 2023, was RMB 1.17, compared to a basic loss per share of RMB 3.61 for the year ended December 31, 2022[2]. - The gross profit for the year ended December 31, 2023, was RMB 691.6 million, reflecting a 10.6% increase from RMB 625.3 million in the previous year[4]. - The company's revenue increased by 12.2% from RMB 1,253.8 million in 2022 to RMB 1,406.2 million in 2023, driven by higher sales of ophthalmic medical consumables and equipment[18]. - Sales of distributed products reached RMB 808.9 million in 2023, up from RMB 744.8 million in 2022, while proprietary products sales increased from RMB 308.3 million to RMB 381.9 million[19]. - Gross profit increased by 10.6% from RMB 625.3 million in 2022 to RMB 691.6 million in 2023, with a slight decrease in gross margin from 49.9% to 49.2%[21]. - The total comprehensive income for the year was RMB 208,753 thousand, compared to a loss of RMB 328,210 thousand in 2022[63]. Revenue Breakdown - Revenue from proprietary products reached RMB 381.9 million, accounting for 32.1% of total sales, up from 29.3% in the previous year[7]. - Revenue from distribution products was RMB 808.9 million, an increase of 8.6% from RMB 744.8 million in the previous year[8]. - The technical services segment generated revenue of RMB 209,234 thousand, up from RMB 190,084 thousand in 2022, showing a growth of approximately 10.6%[84]. - Revenue from the Greater China region was RMB 1,122,722 thousand, up from RMB 1,001,358 thousand in 2022, reflecting a growth of about 12.1%[81]. Research and Development - The R&D team has 240 personnel, accounting for approximately 28% of total employees, with R&D expenditure of RMB 52.9 million, representing 13.9% of proprietary product revenue, an increase of 28.7% from RMB 41.1 million in 2022[10]. - The company aims to increase R&D investment and enhance cooperation with upstream partners to achieve over 50% revenue contribution from proprietary products[17]. - The company’s R&D efforts include the development of an automatic fundus camera and optical biometer, with the automatic fundus camera showing increasing market demand[11]. - Research and development expenses amounted to RMB 52,883,000, up from RMB 41,089,000 in the previous year, marking a growth of 28.7%[92]. Expenses and Costs - The cost of sales rose by 13.7% from RMB 628.4 million in 2022 to RMB 714.6 million in 2023, primarily due to increased raw material costs for proprietary products and higher procurement prices for imported products[20]. - Sales and distribution expenses surged by 32.5% from RMB 187.8 million in 2022 to RMB 248.8 million in 2023, attributed to the resumption of offline marketing activities post-pandemic[23]. - Administrative expenses decreased by 11.5% from RMB 146.2 million for the year ended December 31, 2022, to RMB 129.4 million for the year ended December 31, 2023, primarily due to the absence of listing expenses in 2023[24]. - Financing costs increased by 18.5% from RMB 42.7 million for the year ended December 31, 2022, to RMB 50.6 million for the year ended December 31, 2023, mainly due to rising interest rates on bank and other borrowings[25]. Dividends and Shareholder Returns - The company plans to distribute a final dividend of HKD 1.1 per share for the year ended December 31, 2023, subject to shareholder approval[2]. - The company proposed a final dividend of HKD 1.10 per share for the year ending December 31, 2023, compared to no dividend in 2022, amounting to HKD 162,767,000[102]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and has adopted a corporate governance code[54]. - The chairman and CEO roles are held by the same individual, which the board believes does not affect the balance of power and authority[55]. - The company has established an audit committee to oversee financial reporting and risk management processes[58]. Market Expansion and Strategy - The company has expanded its distribution network, partnering with 19 overseas brands, including Haag-Streit, to enhance its product offerings and market reach[12]. - The company is expanding its market presence in the Greater China region, targeting a 25% increase in market share by 2025[125]. - The company plans to strengthen its market presence in Asia and Europe while balancing domestic and international business growth[17]. Assets and Liabilities - Non-current assets increased to RMB 1,452,881 thousand as of December 31, 2023, from RMB 1,391,756 thousand in 2022[64]. - The company's total equity increased to RMB 1,696,986 thousand as of December 31, 2023, compared to RMB 1,486,685 thousand in 2022[66]. - The total amount of borrowings as of December 31, 2023, was RMB 618,562,000, compared to RMB 701,588,000 in 2022, showing a decrease of 11.8%[118]. Future Outlook - The company has provided a revenue guidance of $85 million for the fiscal year 2024, which reflects a projected growth of approximately 13%[125]. - New product launches are expected to contribute an additional $10 million in revenue in 2024, focusing on innovative medical devices[125]. - The board of directors remains optimistic about the long-term growth trajectory, citing strong fundamentals and a robust pipeline of new products[125].

Financial Performance - The company reported revenue of RMB 700.7 million for the six months ended June 30, 2023, representing a 21.2% increase from RMB 577.9 million in the same period of 2022[19]. - The net profit for the company was RMB 110.4 million, compared to a net loss of RMB 53.3 million in the same period of 2022, marking a significant turnaround[19]. - Basic earnings per share increased to RMB 0.75, compared to a basic loss per share of RMB 0.54 in the same period of 2022[19]. - The gross profit for the six months ended June 30, 2023, was RMB 355.6 million, reflecting a 26.5% increase from the previous year[20]. - The company's other income and gains rose from RMB 13.9 million to RMB 21.8 million, mainly due to foreign exchange gains of RMB 7.3 million in the first half of 2023 compared to a loss of RMB 84.6 million in the same period of 2022[36]. - The company reported a total comprehensive income of RMB 147,170 thousand for the period, compared to a loss of RMB 65,286 thousand in the same period last year[85]. - The company reported a net cash flow from operating activities of RMB 111,187,000 for the six months ended June 30, 2023, compared to RMB 75,268,000 for the same period in 2022, representing a year-over-year increase of about 47.8%[92]. - The company reported a pre-tax profit of RMB 142,229,000 for the six months ended June 30, 2023, compared to a loss of RMB 32,147,000 in the same period of 2022[114]. Research and Development - Research and development expenses were RMB 26.1 million, up 16.5% from RMB 22.4 million in the same period of 2022, maintaining a stable ratio of approximately 3.7% of revenue[19]. - The company has established a "global 4+2" R&D layout with seven R&D and production platforms in China and two overseas in the Netherlands and Germany[20]. - The company continues to invest in R&D and has appointed Dr. Alexey Nikolaevich Simonov as the Chief Technology Officer[20]. - R&D expenditure was RMB 26.1 million, accounting for 3.7% of total revenue, a 16.5% increase from RMB 22.4 million in the same period last year[26]. - The company aims to enhance its proprietary product revenue share and increase investment in surgical treatment products while maintaining its leading position in diagnostic products[29]. - The company is advancing the registration of the new generation ATOS femtosecond corneal refractive surgery system and the ANTERION multimodal imaging platform[28]. - The company has invested 10 million euros in R&D for the development of innovative glaucoma treatments[151]. Sales and Market Presence - Sales of proprietary products reached RMB 193.9 million, accounting for 32.7% of total product sales, setting a new record[20]. - Revenue from proprietary products reached RMB 193.9 million, accounting for 32.7% of total sales, a 36.5% increase from RMB 142.0 million in the same period last year[23]. - Revenue from distribution products was RMB 399.4 million, representing 67.3% of total sales, up 17.9% from RMB 338.7 million year-over-year[24]. - The company serves over 4,000 end customers in China, including more than 1,200 tertiary hospitals and 1,500 secondary hospitals[20]. - The company has partnered with 19 overseas brand partners, with 17 having exclusive distribution agreements, including two new partners added during the reporting period[20]. - The company is expanding its market presence in Asia, targeting a 25% increase in market share by the end of 2024[151]. Expenses and Costs - Selling and distribution expenses increased by 34.2% to RMB 120.9 million, representing 17.3% of revenue, up from 15.6% in the previous year[37]. - Administrative expenses decreased by 10.5% to RMB 62.5 million, primarily due to the absence of listing expenses incurred in the previous year[38]. - Financing costs slightly increased from RMB 20.7 million to RMB 23.7 million, attributed to higher interest expenses on domestic loans and preferred financing loans[39]. - The cost of goods sold increased to RMB 345,096,000, up from RMB 296,633,000, representing a growth of approximately 16.3% year-over-year[106]. - Employee benefits expenses amounted to RMB 48,467,000 for the six months ended June 30, 2023, compared to RMB 44,297,000 for the same period in 2022, reflecting an increase of about 4.9%[107]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 1,969,859 thousand, an increase from RMB 2,225,467 thousand as of December 31, 2022[86]. - Current liabilities increased to RMB 878,342 thousand from RMB 492,623 thousand at the end of the previous year[86]. - Cash and cash equivalents decreased by 10.9% from RMB 721.5 million as of December 31, 2022, to RMB 642.5 million as of June 30, 2023, due to the use of operating surplus funds for investments in financial assets[55]. - Trade receivables decreased from RMB 166.4 million as of December 31, 2022, to RMB 158.9 million as of June 30, 2023, due to improved collection management[49]. - Trade payables increased from RMB 68.7 million as of December 31, 2022, to RMB 96.6 million as of June 30, 2023, primarily due to preemptive stockpiling after the lifting of pandemic control measures[50]. - The debt-to-asset ratio improved from 50.9% as of December 31, 2022, to 46.1% as of June 30, 2023[57]. Corporate Governance and Management - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with applicable corporate governance codes[64]. - The company has adopted a code of conduct for securities trading, ensuring all directors complied with the standards during the reporting period[65]. - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2023[66]. - The company has no other disclosure obligations under the Listing Rules apart from what is disclosed in the interim report[79]. - The company has maintained a stable relationship with its related parties, with minimal transactions reported in the current period compared to the previous year[137]. Future Outlook - The company plans to focus on obtaining regulatory approvals for new products and expanding its market presence in the second half of 2023[30]. - The company aims to leverage its product line and brand advantages to ensure favorable bidding outcomes for its ophthalmic products[30]. - The company plans to increase its workforce by 15% to support its expansion and R&D efforts[151]. - A strategic acquisition of a technology firm is anticipated to enhance the company's R&D capabilities and product offerings[150].

[41 -> 70] 各位参议师以及投资者朋友们,大家上午好。欢迎各位出席高市医疗2023年度中期业绩发布会。首先,我们有请田圆女士做开场介绍。大家好,欢迎各位参会。首先介绍一下,参加本次发布会的公司管理层代表有高市医疗创始人、董事长兼首席执行官高铁塔先生、联席CEO兼执行董事刘新伟先生、 [70 -> 96] 以及首席财务官执行董事,尽涉及内在风险及不确定因素,可能导致实际业绩偏离当前的预期。有关该等风险及不确定因素的详细论述,请参阅高市医疗向香港交易所递交的最新公告内容。 [96 -> 126] 本次会议中所提供的一切紧张性陈述均基于我们认为截至今日合理的假设高市医疗并不承担更新该等陈述的任何义务除非适用法律另有规定本次讨论还包含某些非国际财务报告准则的财务措施仅供比较之用稍后刘兴伟先生将首先向大家介绍高市医疗的业务发展情况及未来展望第二部分由李文琪女士帮我们回顾公司的财务表现 [126 -> 156] 在管理层的讲解之后 在管理层的讲解之后 我们将会举行一个简单的问答环节 我们将会举行一个简单的问答环节 各位如需与管理层进行线上提问 各位如需与管理层进行线上提问 可通过举手语音提问或文字提问 可通过举手 ...

Financial Performance - For the six months ended June 30, 2023, the company recorded revenue of RMB 700.7 million, an increase of 21.2% compared to RMB 577.9 million for the same period in 2022[2]. - The net profit for the six months ended June 30, 2023, was RMB 110.4 million, a significant recovery from a net loss of RMB 53.3 million in the same period of 2022, and an increase of 22.0% compared to the adjusted net profit of RMB 90.5 million for 2022[2][5]. - The gross profit for the six months ended June 30, 2023, was RMB 355.6 million, representing a 26.5% increase from RMB 281.2 million in the previous year[5]. - Total revenue for the six months ended June 30, 2023, was RMB 700.7 million, a 21.2% increase from RMB 577.9 million for the same period in 2022[17]. - Gross profit increased by 26.5% to RMB 355.6 million, with a gross margin improvement from 48.7% to 50.8%[19]. - The total comprehensive income for the period was RMB 147,170 thousand, compared to a loss of RMB 65,286 thousand in the previous year[60]. - The net profit attributable to the owners of the parent company for the period was RMB 110,421 thousand, compared to a loss of RMB 53,264 thousand in the previous year[57]. - Basic earnings per share for the period was RMB 0.75, a recovery from a loss of RMB 0.54 per share in the prior year[57]. Research and Development - Research and development expenses amounted to RMB 26.1 million, up 16.5% from RMB 22.4 million in the same period of 2022, maintaining a stable ratio of approximately 3.7% of revenue[2][3]. - The company has established a "global 4+2" R&D layout with seven R&D and production platforms in China and two overseas in the Netherlands and Germany, covering sales in 51 countries and regions[4]. - The group aims to enhance its product line through mergers and acquisitions while increasing R&D investment to boost the proportion of self-owned product revenue[14]. - The group has established a "global 4+2" R&D layout with 211 R&D personnel, averaging over ten years of industry experience, and production facilities exceeding 14,000 square meters[11]. - The company plans to invest €10 million in research and development over the next year to innovate new technologies[101]. Product Revenue - Revenue from proprietary products reached RMB 193.9 million, accounting for 32.7% of total product sales, a 36.5% increase from RMB 142.0 million in the same period of 2022[8]. - Revenue from distribution products contributed RMB 399.4 million, representing 67.3% of total product sales, an increase of 17.9% from RMB 338.7 million in the previous year[9]. - Revenue from self-owned products was RMB 193,868,000, up from RMB 141,991,000, representing a 36.5% increase year-over-year[70]. - Sales of ophthalmic medical devices contributed RMB 337.9 million, up from RMB 274.5 million, with a gross margin of 48.7%[20]. Expenses and Costs - Selling and distribution expenses increased by 34.2% to RMB 120.9 million, representing 17.3% of total revenue, up from 15.6%[22]. - Administrative expenses decreased by 10.5% to RMB 62.5 million, attributed to the absence of listing expenses following the company's IPO[23]. - The total employee cost for the six months ended June 30, 2023, was RMB 169.6 million, compared to RMB 143.8 million for the same period in 2022[47]. - Financing costs increased slightly to RMB 23.7 million due to higher interest expenses on domestic loans and preferred financing loans[24]. Assets and Liabilities - As of June 30, 2023, the company's cash and cash equivalents amounted to RMB 642.5 million, a decrease of 10.9% from RMB 721.5 million as of December 31, 2022[40]. - Total liabilities increased significantly to RMB 1,212,798 thousand, up 56.5% from RMB 792,405 thousand as of December 31, 2022[64]. - The debt-to-asset ratio as of June 30, 2023, was 46.1%, down from 50.9% as of December 31, 2022[43]. - Trade receivables decreased from RMB 166.4 million as of December 31, 2022, to RMB 158.9 million as of June 30, 2023, due to improved collection management[34]. - Inventory increased from RMB 281.1 million as of December 31, 2022, to RMB 305.3 million as of June 30, 2023, reflecting changes in finished goods based on sales plans[33]. Market and Strategic Initiatives - The company has partnered with 19 overseas brands, with 17 having exclusive distribution agreements, including two new partners added during the reporting period[4][9]. - The company is focusing on maximizing operational efficiency and expanding market space in the second half of 2023, with specific attention to the registration progress of RGP products and the new generation navigation femtosecond refractive surgery system ATOS[15]. - The company plans to expand its market presence and enhance product offerings through ongoing research and development initiatives[99]. - The company is expanding its market presence in Europe, targeting a 25% increase in market share by the end of 2024[102]. Taxation - The company has maintained a favorable tax rate of 15% for its subsidiary recognized as a "High-tech Enterprise" in China, compared to the standard rate of 25%[79]. - The total tax expense for the six months ended June 30, 2023, was RMB 31,808,000, compared to RMB 21,117,000 for the same period in 2022, representing a 50.3% increase[81]. - The company anticipates that the tax deduction rate for R&D expenses will be increased to 100% starting from January 1, 2023, which may positively impact future profitability[83]. Corporate Governance - The company has adopted a corporate governance code to ensure accountability and protect shareholder interests, although the roles of Chairman and CEO are held by the same individual[52]. - The audit committee has reviewed the interim financial statements, confirming compliance with applicable accounting standards and regulations[54].

Financial Performance - Revenue for 2022 was RMB 1,253.8 million, a decrease of 3.4% compared to RMB 1,298.2 million in 2021[6] - Net loss for 2022 was RMB 352.7 million, an increase of 84.1% compared to RMB 191.6 million in 2021[6] - Adjusted net profit (non-IFRS measure) for 2022 was RMB 157.3 million, a decrease of 8.2% compared to RMB 171.3 million in 2021[6] - Basic loss per share for 2022 was RMB 3.61, an increase of 81.4% compared to RMB 1.99 in 2021[6] - Revenue for 2022 was RMB 1,253.8 million, a decrease of 3.4% compared to the previous year[11] - Gross profit increased to RMB 625.3 million in 2022, up by 2.6% year-over-year[11] - Sales of ophthalmic medical equipment decreased to RMB 641.3 million in 2022 from RMB 718.7 million in 2021[12] - Sales of ophthalmic medical consumables increased to RMB 411.8 million in 2022 from RMB 408.4 million in 2021[12] - Technical service revenue rose to RMB 190.1 million in 2022 from RMB 161.6 million in 2021[12] - Revenue decreased by 3.4% from RMB 1,298.2 million in 2021 to RMB 1,253.8 million in 2022 due to the impact of COVID-19, particularly in December 2022[24][26] - Sales of ophthalmic medical equipment decreased by RMB 77.4 million, partially offset by an increase in technical service revenue of RMB 28.5 million and ophthalmic medical consumables revenue of RMB 3.4 million[26] - Gross profit increased by 2.6% to RMB 625.3 million in 2022, with gross margin improving from 46.9% in 2021 to 49.9% in 2022[29] - Gross margin for ophthalmic medical consumables increased to 55.6% in 2022 from 51.2% in 2021, while gross margin for technical services rose to 48.0% from 43.4%[30] - Sales and distribution expenses decreased slightly by 0.9% to RMB 187.8 million in 2022, accounting for 15.0% of revenue compared to 14.6% in 2021[32] - Administrative expenses increased by 11.2% to RMB 146.2 million in 2022, driven by higher personnel costs and listing-related expenses[33] - Other income and gains decreased significantly to RMB 21.1 million in 2022 from RMB 77.9 million in 2021, mainly due to foreign exchange losses of RMB 172.5 million[31] - Financing costs decreased by 48.9% from RMB 83.5 million in 2021 to RMB 42.7 million in 2022, primarily due to the repayment of interest-bearing loans[34] - R&D costs increased by 74.8% from RMB 23.5 million in 2021 to RMB 41.1 million in 2022, driven by team expansion and R&D center upgrades[35] - The fair value loss on convertible redeemable preferred shares decreased from RMB 375.6 million in 2021 to RMB 307.4 million in 2022 due to changes in the company's valuation[36] - Other expenses surged from RMB 21.7 million in 2021 to RMB 196.4 million in 2022, mainly due to increased exchange losses on preferred shares[36] - Income tax expenses rose by 44.8% from RMB 53.6 million in 2021 to RMB 77.6 million in 2022, reflecting higher taxable profits[37] - The company recorded a net loss of RMB 352.7 million in 2022, compared to a net loss of RMB 191.6 million in 2021[38] - Adjusted net profit (non-IFRS) decreased by 8.2% from RMB 171.3 million in 2021 to RMB 157.3 million in 2022, impacted by pandemic control policies and increased R&D expenses[39] - Inventory increased by 17.1% from RMB 240.1 million in 2021 to RMB 281.1 million in 2022, with inventory turnover days rising from 129 days to 155 days[41] - Trade receivables decreased by 4.7% from RMB 180.2 million in 2021 to RMB 171.7 million in 2022, with turnover days remaining stable at 50-51 days[42] - Goodwill increased by 2.7% from RMB 882.7 million in 2021 to RMB 906.9 million in 2022, mainly due to exchange rate fluctuations between RMB and EUR[45] - Intangible assets decreased by 8.2% from RMB 303.9 million as of December 31, 2021, to RMB 278.9 million as of December 31, 2022, primarily due to accumulated amortization[46] - Cash and cash equivalents increased by 18.5% from RMB 609.0 million as of December 31, 2021, to RMB 721.5 million as of December 31, 2022, driven by IPO proceeds and increased operating cash flow[47] - Capital expenditures increased by 71.2% from RMB 28.0 million in 2021 to RMB 48.0 million in 2022, mainly for production-related equipment and daily renovation expenses[49] - The asset-liability ratio improved to 50.9% as of December 31, 2022, compared to a negative 151.8% as of December 31, 2021, due to the elimination of net liabilities under IFRS[50] - The company repaid a total of EUR 11.25 million of long-term loans from Swiss banks and EUR 25.0 million of mezzanine financing loans in 2022[47] - The effective annual interest rate for bank and other borrowings ranged from 1.50% to 7.00% as of December 31, 2022, with remaining loan terms ranging from less than one year to three years[48] - The company recorded a foreign exchange gain of RMB 24.5 million in 2022, compared to a loss of RMB 58.6 million in 2021, due to fluctuations in the Euro exchange rate[52] - The company has no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures as of December 31, 2022[54] - The company has no significant future plans for investments or capital assets beyond those disclosed in the annual report and prospectus[55] - The company maintains a robust liquidity position with sufficient cash and bank balances to meet operational needs and support expansion plans[47] - The company's global offering generated net proceeds of approximately HKD 284.71 million after deducting underwriting fees, commissions, and other estimated expenses[78] - Net proceeds of HKD 284.71 million were utilized as of December 31, 2022, with HKD 216.27 million remaining unused[80] - 38.2% of net proceeds (HKD 108.76 million) allocated to R&D and patent commercialization, expected to be fully utilized by December 11, 2024[80] - 29.0% of net proceeds (HKD 82.56 million) allocated to capacity expansion and manufacturing enhancement, expected to be fully utilized by December 11, 2024[80] - 9.5% of net proceeds (HKD 27.05 million) allocated to sales and marketing expansion, expected to be fully utilized by December 11, 2024[80] - 10.6% of net proceeds (HKD 30.18 million) allocated to working capital and general corporate purposes[80] - 12.7% of net proceeds (HKD 36.16 million) allocated to repayment of interest-bearing borrowings[80] - Additional net proceeds of HKD 1.77 million were generated from the partial exercise of the over-allotment option on January 9, 2023[81] - The company had distributable reserves of approximately RMB 822.2 million as of December 31, 2022[87] - The company had a total of 790 employees as of December 31, 2022, with total employee costs amounting to RMB 288.4 million for the year[94] - The company's core values emphasize employee development, with a focus on training and skill enhancement across various levels and positions[94] - The company operates a defined contribution retirement plan, with contributions made based on a percentage of employee salary costs[95] - Liu Xinwei was appointed as Co-CEO and his annual salary was adjusted from RMB 1,070,000 to RMB 1,170,000 effective January 10, 2023[96] - Zhang Jianjun resigned as President and was appointed as Honorary President, with his annual salary adjusted from RMB 1,160,000 to RMB 800,000 effective January 10, 2023[96] - Gao Tieta holds a 42.76% stake in the company through controlled corporate interests, owning 63,263,528 shares[98] - Zhang Jianjun holds a 4.81% stake in the company through controlled corporate interests, owning 7,112,360 shares[98] - Zhao Xinli holds a 2.32% stake in the company through controlled corporate interests, owning 3,436,116 shares[98] - Liu Xinwei holds a 0.65% stake in the company through controlled corporate interests, owning 955,879 shares[98] - No directors or senior executives have rights to acquire shares or debentures of the company or any other corporate body as of December 31, 2022[100] - GT HoldCo holds 63,263,528 shares, representing 42.76% of the company's issued share capital[102] - OrbiMed Asia directly holds 18,039,426 shares, representing 12.19% of the issued share capital[103] - Cuprite Gem directly holds 11,375,840 shares, representing 7.69% of the issued share capital[104] - GT HoldCo had 38,472,296 shares mortgaged to Credit Suisse for a HKD 185,000,000 loan, which was fully repaid by April 6, 2023[103] - The company has no significant legal proceedings or claims pending or threatened against it as of December 31, 2022[109] - The company maintains a minimum public float of 25% of its total issued share capital, as required by the Hong Kong Stock Exchange[111] - Ernst & Young was appointed as the auditor for the fiscal year ending December 31, 2022, and will be proposed for re-election at the upcoming annual general meeting[112] - The company has adopted the Corporate Governance Code as its own governance standard and has complied with all applicable code provisions during the reporting period[114] - The company emphasizes a culture of integrity, ethical behavior, and compliance, with standards integrated into employee training materials and policies such as the Code of Conduct and Anti-Corruption Policy[116] - The company is committed to employee development, workplace safety, diversity, and sustainability, aiming for long-term, stable, and sustainable growth[117] - The Board of Directors consists of 4 executive directors, 2 non-executive directors, and 3 independent non-executive directors, with one independent director possessing appropriate professional qualifications in accounting or financial management[119] - Independent non-executive directors play a crucial role in providing impartial views on strategy, performance, and controls, ensuring shareholder interests are considered[121] - The company has adopted a Board Diversity Policy to enhance efficiency and maintain high governance standards, considering factors such as gender, age, cultural background, and professional experience[122] - The Board's current composition includes directors with diverse expertise in medicine, business administration, finance, and accounting, aged between 41 and 62[122] - The company has implemented a Board Independence Evaluation Mechanism to ensure strong independent elements and effective decision-making[121] - The company has arranged appropriate liability insurance for directors, with coverage reviewed annually[118] - The Board has delegated specific oversight responsibilities to three committees: Audit, Remuneration, and Nomination Committees[118] - The company aims to appoint at least one female director within one year of the listing date and achieve a target of no less than 20% female representation on the board within five years, subject to satisfaction of candidates' qualifications and experience[123] - As of December 31, 2022, the company had 790 full-time employees, with female employees accounting for approximately 36.7% of the workforce, achieving a relatively balanced gender ratio[123] - The company has set measurable goals, including having at least one female member in the senior management team and maintaining at least 35% female representation among full-time employees[123] - Li Wenqi, a female executive, was appointed as the company's CFO in January 2023, responsible for the group's overall financial management[123] - The company provides necessary induction training and regular updates to newly appointed directors to ensure they are well-informed about the company's operations and regulatory responsibilities[124] - Directors are encouraged to participate in continuous professional development programs to enhance their knowledge and skills, with external legal counsel providing training on regulatory updates[124] - The Chairman and CEO roles are held by the same individual, Gao Tieta, due to his extensive experience and understanding of the company's business, which facilitates strategic execution and information flow[126] - The company's board consists of experienced and talented individuals, with decisions requiring approval by at least a majority of the directors, ensuring checks and balances[126] - Executive and non-executive directors have service contracts with the company, initially for three years from the listing date, renewable under applicable laws and regulations[127] - Independent non-executive directors have appointment letters with the company, also initially for three years from the listing date, renewable under applicable laws and regulations[127] - The company will hold at least four regular board meetings in the fiscal year ending December 31, 2023[128] - The board chairman will hold at least one meeting with independent non-executive directors without the presence of other directors in the fiscal year ending December 31, 2023[128] - The audit committee reviewed the audited consolidated financial statements and annual results for the year ended December 31, 2022, during its meeting on March 31, 2023[133] - The audit committee also reviewed the effectiveness of the company's financial reporting, risk management, and internal control systems during the March 31, 2023 meeting[133] - The nomination committee is responsible for reviewing the board's structure, size, and composition at least annually and making recommendations for changes to align with the company's corporate strategy[134] - The nomination committee is tasked with identifying and evaluating candidates for board and senior management positions, including assessing the balance of skills, knowledge, and experience on the board[134] - The board retains decision-making authority over all significant matters, including policy approval, overall strategy, budgets, internal controls, risk management systems, and major transactions[130] - The company has adopted a code of conduct for securities transactions by directors and employees, with terms no less stringent than the standard code[129] - The board is collectively responsible for corporate governance, including reviewing and monitoring compliance with legal and regulatory requirements[131] - The audit committee is responsible for overseeing the company's financial reporting system, risk management, and internal control systems[132] - The company held its first nomination committee meeting on March 31, 2023, where it reviewed the composition of the board and its committees, recommended the re-election of retiring directors, and proposed the appointment of Dr. Alexey Nikolaevich Simonov as Chief Technology Officer[135] - The nomination committee evaluates candidates based on diversity factors including gender, age, cultural and educational background, race, professional experience, skills, knowledge, and tenure, as well as their potential contributions to shareholder value[137] - The nomination process includes consulting various sources, assessing candidates through interviews and background checks, and making recommendations to the board, which has the final authority to appoint directors[138] - The remuneration committee reviewed and recommended the compensation for directors and senior management for the year ending December 31, 2023, including adjustments for some executive directors and senior management[140] - The company's director remuneration policy includes a fixed component (base salary) and a variable component (discretionary bonuses and other incentives), considering factors such as experience, responsibility level, individual performance, and market conditions[141] - The total remuneration for audit and non-audit services provided by the auditor in 2022 amounted to RMB 19,519 thousand, with audit services accounting for RMB 17,587 thousand and non-audit services for RMB 1,932 thousand[145] - The company has established a robust risk management and internal control system, which is reviewed annually by the Board to ensure effectiveness and compliance with legal and regulatory requirements[150] - The company has adopted an anti-corruption policy and a whistleblowing policy to promote ethical behavior, compliance, and good corporate governance, with no significant fraud or misconduct reported for the year 2022[147][148] - The company maintains a high level of corporate governance, with monthly updates provided to the Board on the group's performance, status, and prospects[144] - The company has implemented an insider information management system to ensure timely disclosure of material information and strict control over information dissemination[149] - The company's internal audit function plays a key role in monitoring internal governance, with findings reported to the Audit Committee and, if necessary, to the Board[149] - The company's risk management system includes clear division of responsibilities and authority, regular compliance training for employees, and mechanisms for identifying and mitigating potential risks[149] - The company's ESG-related resources, staff qualifications, training programs, and budgets are deemed sufficient by the Board, with ESG risks included in the risk management framework[150] - The company's corporate governance framework emphasizes high standards of integrity, transparency, and ethical business practices, supported by policies such as the anti-corruption and whistleblowing policies[146][147] - The company's financial statements for 2022 were prepared in accordance with applicable standards, with no significant uncertainties identified that could cast doubt on the group's ability to continue as a going concern[144] - The company has no specific dividend policy or predetermined payout ratio, and future dividend payments will be determined by the board based on profits, cash flow, financial condition, capital requirements, and other relevant factors[152] - The company held its IPO on December 12, 2022, and has not yet held an annual general meeting since listing[153] - The company has established multiple channels for shareholder communication, including annual reports, interim reports, circulars, regular announcements